Your browser is no longer supported. Please, upgrade your browser.
Index- P/E- EPS (ttm)-6.28 Insider Own13.98% Shs Outstand17.61M Perf Week-4.66%
Market Cap130.24M Forward P/E- EPS next Y-3.33 Insider Trans-0.24% Shs Float14.95M Perf Month-31.86%
Income-49.20M PEG- EPS next Q-0.81 Inst Own83.00% Short Float4.09% Perf Quarter-49.42%
Sales- P/S- EPS this Y-149.70% Inst Trans12.92% Short Ratio5.21 Perf Half Y-64.40%
Book/sh4.79 P/B1.45 EPS next Y6.20% ROA-47.70% Target Price- Perf Year-56.29%
Cash/sh4.71 P/C1.48 EPS next 5Y- ROE-50.40% 52W Range6.61 - 62.71 Perf YTD-68.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-89.17% Beta-
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low2.72% ATR0.49
Employees27 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)23.69 Volatility6.56% 6.06%
OptionableNo Debt/Eq0.00 EPS Q/Q53.80% Profit Margin- Rel Volume0.23 Prev Close6.95
ShortableYes LT Debt/Eq0.00 EarningsMar 05 BMO Payout- Avg Volume117.42K Price6.79
Recom1.50 SMA20-15.54% SMA50-35.81% SMA200-62.52% Volume26,608 Change-2.30%
Aug-17-20Upgrade Citigroup Neutral → Buy $34 → $30
Jun-30-20Downgrade Citigroup Buy → Neutral $30 → $34
Apr-06-20Initiated SVB Leerink Outperform $25
Apr-06-20Initiated Morgan Stanley Overweight $35
Apr-06-20Initiated Cowen Outperform $25
Mar-29-21 07:00AM  
Mar-22-21 04:05PM  
Mar-17-21 07:00AM  
Mar-15-21 11:00AM  
Mar-14-21 08:16PM  
Mar-12-21 05:45AM  
Mar-10-21 02:40AM  
Mar-05-21 07:00AM  
Feb-26-21 09:30PM  
Feb-19-21 07:00AM  
Jan-20-21 07:00AM  
Jan-06-21 05:21PM  
Dec-10-20 01:01AM  
Dec-07-20 07:00AM  
Nov-30-20 10:36PM  
Nov-17-20 07:00AM  
Nov-05-20 07:00AM  
Oct-31-20 08:00AM  
Oct-29-20 07:00AM  
Oct-16-20 07:00AM  
Sep-02-20 07:00AM  
Aug-25-20 07:00AM  
Aug-14-20 08:26AM  
Aug-13-20 04:01PM  
Aug-07-20 07:00AM  
Jul-30-20 07:00AM  
Jun-29-20 04:01PM  
Jun-25-20 07:00AM  
Jun-24-20 07:00AM  
Jun-22-20 01:57PM  
Jun-13-20 08:44AM  
Jun-12-20 07:46AM  
May-21-20 07:00AM  
May-07-20 07:00AM  
May-06-20 07:00AM  
May-04-20 07:00AM  
Apr-23-20 07:00AM  
Mar-11-20 09:57PM  
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and -thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ballal Rahul D.Chief Executive OfficerDec 17Option Exercise3.154,99915,7474,999Dec 21 04:47 PM
Ballal Rahul D.Chief Executive OfficerDec 17Sale25.004,999124,9750Dec 21 04:47 PM
GRAY MICHAELCFO & COODec 11Option Exercise4.921,2506,1501,250Dec 15 04:26 PM
GRAY MICHAELCFO & COODec 11Sale25.001,25031,2500Dec 15 04:26 PM